T. Mamounas

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

Erica L. Mayer, Dominik Hlauschek, Michael Gnant, Patrick O’Brien et autres

BACKGROUND: In the phase III PALLAS trial, the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) did not improve short-term invasive disease-free survival (iDFS) compared with ET alone in high-risk early-stage hormone receptor (HR)-positive/human epidermal growth factor receptor 2 …

us, at, es, mx, gb, ie, au, tw, hu, se, pl, ch, be (code pays fourni par la source)

307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial

Vesna Bjelic‐Radisic, L. Sölkner, Angela DeMichele, M. Naughton et autres

PALLAS is a prospective, randomised, open-label, multi-centre phase III trial comparing the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) versus ET-alone, in patients (pts) with HR+/HER2- early breast cancer (BC), capturing long term clinical outcomes, physician-graded toxicity by …

de, at, us, ca, gb, es, jp (code pays fourni par la source)

Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux et autres

Abstract PURPOSE: Results from adjuvant trials evaluating 6 cycles of epirubicin-based chemotherapy regimens suggested these programs may be more effective than 4 cycles of doxorubicin-based chemotherapy. METHODS: NSABP B-36 was a phase III clinical trial originally designed as a 2x2 factorial study …

us, ca, in (code pays fourni par la source)

96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE

Sibylle Loibl, Chiun‐Sheng Huang, Max S. Mano, T. Mamounas et autres

de, tw, br, us, fr, se, ch (code pays fourni par la source)

Personalizing Treatment for Node-Positive, ER-Positive Breast Cancer

T. Mamounas

breast cancer; genomics: breast cancer; genomicsOver the past decade, genomic profiling of the primary breast tumor has become a well-accepted approach for estimating prognosis and predicting benefit from adjuvant chemotherapy in patients with node-negative and estrogen receptor (ER)-positive breast cancer (N Engl …

Abstract P6-08-06: The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early stage hormone receptor-positive (HR+), HER2– breast cancer (BC) patients for whom multigene assays may be valuable

Matti Aapro, Juan Enrique Bargalló Rocha, Roberto Elizalde, László Landherr et autres

Abstract Background Treatment recommendations for early stage HR+, HER2– BC patients depend on many factors. The MAGIC survey evaluated which criteria clinicians use regarding the need for adjuvant chemotherapy (AdjCT) and showed that there was substantial heterogeneity across clinicians and countries in …

ch, co, in, se, us, es, be, gb, fr, nl, kr (code pays fourni par la source)

Elderly patients with early breast cancer (BC) are less likely to receive adjuvant chemotherapy (AdjCT) irrespective of disease risk factors: The multidisciplinary application of genomics in clinical practice (MAGIC) survey

Christos Markopoulos, Matti Aapro, Juan Enrique Bargalló Rocha, Michelino De Laurentiis et autres

ch, mx, it, hu, se, us, es, be, ru, gb, fr, nl, de (code pays fourni par la source)

Recurrence Score and Quantitative Er Expression Predicts Late Distant Recurrence Risk in Er+ Bc After Five Years of Tamoxifen

T. Mamounas, Norman Wolmark, Frederick L. Baehner, Steven M. Butler et autres

us (code pays fourni par la source)

The Effect of Physician'S Characteristics on Adjuvant Chemotherapy (Ct) Decisions for Early Stage Hr + , Her2– Breast Cancer (Bc) Patients (Pts)

Michelino De Laurentiis, Matti Aapro, Christos Markopoulos, T. Mamounas et autres

in, it, ch, gr, us, fr, de, mx, gb, be, se, nl, hu, es (code pays fourni par la source)

Traditional Prognostic Factors Used for Adjuvant Chemotherapy (Ct) Decisions in Early Stage Hr + , Her2– Breast Cancer in a Large International Survey (Magic) Among Breast Cancer Specialists

Miguel Martín, Matti Aapro, Christos Markopoulos, T. Mamounas et autres

es, ch, gr, us, fr, de, mx, gb, be, se, nl, hu, in, it (code pays fourni par la source)

Predicting locoregional recurrence after neoadjuvant chemotherapy in patients with breast cancer.

T. Mamounas

us (code pays fourni par la source)

Improving outcomes in early-stage breast cancer.

Stefan Glück, T. Mamounas

Early-stage breast cancer is a prevalent malignancy that continues to cause a significant number of cancer-related deaths each year. Current evidence points to suboptimal care in patients with early-stage breast cancer, especially with regard to physician use of guideline-recommended care. Such appropriate …

us (code pays fourni par la source)